Back to Search
Start Over
Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment
- Source :
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 28(3)
- Publication Year :
- 2021
-
Abstract
- Introduction Imatinib is generally well tolerated by patients. The most common ophthalmic side effects are eyelid edema and periorbital edema. Other side effects which occur at rates of Case report A 51-year-old male with leukocytosis detected in the blood test examination was referred to the Hematology Department. The bone marrow biopsy result was compatible with chronic myeloid leukemia. Imatinib treatment (400 mg/day) was started. In the ninth month of imatinib treatment, the patient complained of a sudden decrease in vision. Vitreous hemorrhage was detected in the left eye and the patient underwent surgery. Vitreous hemorrhage recurred 1 month after the operation. On the fourth day after the discontinuation of imatinib treatment, the patient's ophthalmic complaints improved significantly. The Naranjo algorithm was applied and a score of 9 was detected. The vitreous hemorrhage of the patient was attributed to imatinib, and so the treatment of the patient was switched to bosutinib. Discussion Imatinib is an oral signal inhibitor that targets tyrosine kinase for BCR/ABL, platelet-derived growth factor, stem cell factor, and c-kit (CD117). The conjunctiva and sclera have a large amount of c-kit positive mast cells which are inhibited by imatinib. The inhibition of c-kit positive mast cells by imatinib may be responsible for further exposure of the conjunctival mucosa to injuries.
- Subjects :
- Male
medicine.medical_specialty
Drug-Related Side Effects and Adverse Reactions
Antineoplastic Agents
Gastroenterology
Piperazines
hemic and lymphatic diseases
Internal medicine
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biopsy
Medicine
Edema
Humans
Pharmacology (medical)
Leukocytosis
medicine.diagnostic_test
biology
business.industry
CD117
Imatinib
Middle Aged
medicine.disease
Vitreous Hemorrhage
medicine.anatomical_structure
Pyrimidines
Oncology
Vitreous hemorrhage
Benzamides
biology.protein
Imatinib Mesylate
Bone marrow
medicine.symptom
business
Tyrosine kinase
Bosutinib
medicine.drug
Subjects
Details
- ISSN :
- 1477092X
- Volume :
- 28
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- Accession number :
- edsair.doi.dedup.....1a5a0e326e1792db2473940c543f7c35